Publications by authors named "Arjun Modi"
Article Synopsis
- CAR T cells are effective against leukemias but struggle with persistence due to the short-lived nature of effector T cells; thus, enhancing CAR T-cell memory is crucial for long-lasting immune protection.
- IL7 receptor (IL7R) signaling is essential for memory T cells, but prolonged exposure to IL7 decreases IL7R surface expression.
- Researchers engineered T cells to either secrete IL7 or express a specific IL7Rα-chimeric cytokine receptor (CCR), ensuring persistent signaling and functionality when combined with a cytotoxic CAR, leading to improved tumor-targeted therapy outcomes.
Discovery and Development of HDAC Inhibitors: Approaches for the Treatment of Cancer a Mini-review.
Curr Drug Discov Technol
September 2024
Histone deacetylase (HDAC) inhibitors have emerged as promising cancer therapeutics due to their ability to induce differentiation, cell cycle arrest, and apoptosis in cancer cells. In the present review, we have described the systemic discovery and development of HDAC inhibitors. Researchers across the globe have identified various small molecules like benzo[d][1,3]dioxol derivatives, belinostat analogs, pyrazine derivatives, quinazolin-4-one-based derivatives, 2,4-imidazolinedione derivatives, acridine hydroxamic acid derivatives, coumarin derivatives, tetrahydroisoquinoline derivatives, thiazole-5-carboxamide, salicylamide derivatives, β-peptoid-capped HDAC inhibitors, quinazoline derivatives, benzimidazole and benzothiazole derivatives, and β- elemene scaffold containing HDAC inhibitors.
View Article and Find Full Text PDFPurpose: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.
Patients And Methods: Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.